A Phase I Dose-Escalation Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of RO7875913 in Healthy Volunteers
Latest Information Update: 23 Jan 2026
At a glance
- Drugs RO 7875913 (Primary)
- Indications Unspecified
- Focus Adverse reactions
- Sponsors Genentech
Most Recent Events
- 23 Jan 2026 New trial record